Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Burosumab for FGF23-Mediated Hypophosphatemia in Fibrous Dysplasia
NCT05509595Phase 2Completed
- Sponsor
- National Institute of Dental and Craniofacial Research
- Start
- Dec 2022
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of burosumab in fibrous dysplasia, hypophosphatemia, sponsored by National Institute of Dental and Craniofacial Research. Started Dec 2022; status: completed.
02
Drugs
burosumab
03
Conditions
fibrous dysplasiahypophosphatemia
Beyond the preview
Go deeper on NCT05509595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05509595.